Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 9 Publications

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NF;2cVFHfW6ldHnvckBCe3OjeR?= M3rWelAvPcLizszN NWfwWpd3OjRiaB?= NHnVSXR4[XSnch?= Mof3cY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM> MX[yOVEzOzB6Mh?=
Eca109 M{jPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TROFAvPS9{LkWvOUDPxE1? MXiyOE81QC95MjDo M{nDcpdifGW{ NYHRRYZUcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M1vQNlI2OTJ|MEiy
Eca109 NX\MW2JoTnWwY4Tpc44hSXO|YYm= NF[1S3oxNjYEoN88US=> NWi4boFzPi9zMj:yOEBp NUjOSnVRf2G2ZYK= Mo[xbY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?= NUjlSZZOOjVzMkOwPFI>
Eca109 M1Kxc2Z2dmO2aX;uJGF{e2G7 M1vBfFAvPcLizszN M3e0NlI1KGh? MVH3ZZRmeg>? MnnhbY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? M17r[|I2OTJ|MEiy
Eca109 NUnnSIFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjFNE42yqEQvF2= MnvDNlQhcA>? NFzRe2V4[XSnch?= NYK4[3RlcW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>? MVuyOVEzOzB6Mh?=
Eca109 MoWzSpVv[3Srb36gRZN{[Xl? NVjKToZlOC53L{Gg{txO MmnWNlQhcA>? NIfDXJd4[XSnch?= NXeyXoZY\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= M{fQSFI2OTJ|MEiy
SW1116  M2PnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;DNE42NzFxMj:1JO69VQ>? NFjHdnM1QCCq MmWxSG1UVw>? NEC1bmJmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v Mom1NlQ5PzR{OE[=
LOVO MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUiwMlUwOS9{L{Wg{txO NFfVVYY1QCCq MkLtSG1UVw>? NE\GOWFmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v MkizNlQ5PzR{OE[=
SW1116  M2S5XGZ2dmO2aX;uJGF{e2G7 NE[xVVEyOCEQvF2= MoDsOFghcA>? NYLoVVA5TE2VTx?= NUXae|lpcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk MmLoNlQ5PzR{OE[=
LOVO NGHreY9HfW6ldHnvckBCe3OjeR?= NVrDUVdKOTBizszN M2SzWFQ5KGh? NUDPNGxxTE2VTx?= M37RNIlv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MWGyOFg4PDJ6Nh?=
SW1116  MnTiRZBweHSxc3nzJGF{e2G7 NHm0cpAyOCEQvF2= NETCdG41QCCq NEjZe5pFVVOR M{TLOIVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> M4Lw[lI1QDd2Mki2
LOVO NVT3UIlxSXCxcITvd4l{KEG|c3H5 NGXY[mIyOCEQvF2= NVHmb4xnPDhiaB?= MVzEUXNQ NXyxcYh7\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MlXNNlQ5PzR{OE[=
RPMI-8226 M3fMSGFxd3C2b4Ppd{BCe3OjeR?= M1rpW|EwOiEQvF2= NWPOTVlGPDhxN{KvPVYhcA>? M4jqeWROW09? NFTG[lFqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NV\kXFlQOjR6M{OxNFg>
OPM-2  MoLZRZBweHSxc3nzJGF{e2G7 M4PaTVEwOiEQvF2= NGjldmI4Oi97Nj:xNlAhcA>? MW\EUXNQ MlvYbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MmLRNlQ5OzNzMEi=
JJN3  NGfqZplCeG:ydH;zbZMhSXO|YYm= Mn;RNE42NzFizszN MVmyOE81QCCq NYPoUVc{TE2VTx?= MWjpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXuyOFg{OzFyOB?=
NCI-H929  Mo\TRZBweHSxc3nzJGF{e2G7 MlfYNU8zKM7:TR?= MXi3Nk86Pi9zMkCgbC=> NUPpblVuTE2VTx?= NWfGe5V2cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= Ml61NlQ5OzNzMEi=
RPMI-8226 M{\hPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\ENU8zKM7:TR?= M3PzUVI1NzR6L{eyJIg> Mlz6SG1UVw>? NGHCbWxi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= M4fY[VI1QDN|MUC4
OPM-2  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\GNU8zKM7:TR?= MVqyOE81QC95MjDo NYnJTVVZTE2VTx?= M4nGVIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NYnFc5MyOjR6M{OxNFg>
JJN3  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHqN3V{OC53L{Gg{txO NXrzboN{OjRxNEivO|IhcA>? MXzEUXNQ MlLHZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NHrKdlgzPDh|M{GwPC=>
NCI-H929  NFLPVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm1S5QyNzJizszN MkTrNlQwPDhxN{KgbC=> MV\EUXNQ M4DPVIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 M{HOdVI1QDN|MUC4
HeLa NHuwcWhMcW6jc3WgRZN{[Xl? NEWy[2dMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy MorsNlQ4QDByOUi=
HeLa MkTKT4lv[XOnIFHzd4F6 NVX6O5JwU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz NH;mVmEzPDd6MEC5PC=>
HeLa MoD2T4lv[XOnIFHzd4F6 M2LYRmtqRTJzLk[gxtEhOy5yIN88UUBnd3JiaFPOWFE> NV3jT45UOjR5OECwPVg>
HeLa NEK1OIZMcW6jc3WgRZN{[Xl? NFH5XIhMcT1zND60JOKyKDRwNjFOwG0h\m:{IHjDUnQ{ MnvlNlQ4QDByOUi=
NB4 NGXDWYFHfW6ldHnvckBCe3OjeR?= M4DNTlIvPS93L{euOU8yOCEQvF2= NFv3bYkzPCCq M{n5WGROW09? NYXQR|JzcW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? NVvGNmRlOjR2OES4O|A>
CD4+ CD25− T  NV\4V297TnWwY4Tpc44hSXO|YYm= MWOxM|Uh|ryP M{jNV5Jm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? MX6yOFQ4PjN4MB?=
BV-173 MYHBdI9xfG:|aYOgRZN{[Xl? MUOwMlI2NzBwNT:wMlc2NzFizszN MYK0PE84Oi97NjDo NYm5T2RSyqCSQmO= NFLNUXFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NF7DXJAzPDR{M{[xNy=>
ML-1 MkP4RZBweHSxc3nzJGF{e2G7 NIrmb3MxNjJ3L{CuOU8xNjd3L{Gg{txO M3rJblQ5Nzd{L{m2JIg> NXSxV5hSyqCSQmO= M3;TV4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M3n1XVI1PDJ|NkGz
HL-60 NX;qTlB6SXCxcITvd4l{KEG|c3H5 NV;ZPYNnOC5{NT:wMlUwOC55NT:xJO69VQ>? M1HpfVQ5Nzd{L{m2JIg> MUpCpHBDWw>? Mn\EbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MmLHNlQ1OjN4MUO=
KG-1a MWXBdI9xfG:|aYOgRZN{[Xl? NW\kN3ZqOC5{NT:wMlUwOC55NT:xJO69VQ>? MoPhOFgwPzJxOU[gbC=> MnTQxsBRSlN? MoK3bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NIPuO20zPDR{M{[xNy=>
BV-173 M{T0UmZ2dmO2aX;uJGF{e2G7 MW[yOVAwPTBybl2= MknqOFghcA>? MYdCpHBDWw>? MkntbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MWSyOFQzOzZzMx?=
CEM MnTaSpVv[3Srb36gRZN{[Xl? MoqyNlUxNzVyMH7N NIWwU|M1QCCq Mn\oxsBRSlN? MU\pcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M4fDfVI1PDJ|NkGz
HL-60 MmXKSpVv[3Srb36gRZN{[Xl? M{HpTFI2OC93MEDuUS=> NIrJbWc1QCCq M{TNbOKhWEKV M2SxbIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= M{LERlI1PDJ|NkGz
ML-1 NWLVb4ZKTnWwY4Tpc44hSXO|YYm= MkKyNlUxNzVyMH7N NVfzT5BRPDhiaB?= NEnC[mHDqFCEUx?= M{PiO4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MmPYNlQ1OjN4MUO=
DLD-1 MXXGeY5kfGmxbjDBd5NigQ>? M2PLWVI2OC93MEDuUS=> M4nX[|Q5KGh? NWDrVW5JyqCSQmO= M{nDToRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MWiyOFQzOzZzMx?=
HCT-116 MWDGeY5kfGmxbjDBd5NigQ>? NGPKWIszPTBxNUCwcm0> M4q4c|Q5KGh? NUXVZVhbyqCSQmO= MX7kc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm MoLSNlQ1OjN4MUO=
U937-A/E-9/14/18  MXPBdI9xfG:|aYOgRZN{[Xl? Mn;rNE4xOS9yLkGvNU8yOCEQvF2= MXe0PEBp MXLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NX\hc3htOjR|MEC0OVY>
HT29 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDLNpI4OiCq Mn6wTWM2OD1zNECwxtEyPzlizszN MnjHNlQyPzJyNkG=
SW48 M2O3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq0NGMzPzJiaB?= MkPDTWM2OD1zNT6yxtE3NjJizszN NHPaNHozPDF5MkC2NS=>
HCT116 M{nJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGwO|IhcA>? M{DVeWlEPTB;MT63xtExNjRizszN M3jpNFI1OTd{ME[x
HepG2 MkXESpVv[3Srb36gRZN{[Xl? MkD4NE42NzFizszN NVXNeGtvOjRiaB?= MV7EUXNQ MoH3eZAuemWpdXzheIVlKHSqZTDy[YxifGm4ZTDPR3RPOiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NY\OboJjOjRzNE[4O|Q>
LS174T MVPGeY5kfGmxbjDBd5NigQ>? MoDYNE42NzFizszN NGXLN|czPCCq NITLWm5FVVOR MVXs[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?= NE\YflkzPDF2Nki3OC=>
HepG2 MnvhRZBweHSxc3nzJGF{e2G7 NI\LXm0yNzFyL{GwNEDPxE1? M4LSWVch\A>? NUPwfpR2TE2VTx?= NUPQem9ucW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MnnNNlQyPDZ6N{S=
LS174T NIDldZJCeG:ydH;zbZMhSXO|YYm= MmrKNU8yOC9zMECg{txO NEH4TVI4KGR? M3fDXWROW09? MXHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2\n[FI1OTR4OEe0
QBC-939 NYiyTJpGSXCxcITvd4l{KEG|c3H5 MnfSNU8yOC9zMECg{txO MX:3JIQ> M{fmUGROW09? NEnrVolqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYXYb|BPOjRzNE[4O|Q>
U251 NHzkOVdCeG:ydH;zbZMhSXO|YYm= NID2UmgyNzFyL{GwNEDPxE1? NW\QUGJ5PyCm M4DmdmROW09? M1nUPYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M17tVFI1OTR4OEe0
HL-60 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL3OnEyKM7:TR?= M3\PRVQ5KGh? NUi4[2ZZcW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36= MoS1NlQxODB|MkS=
MDA‑MB‑453 MnWySpVv[3Srb36gRZN{[Xl? M3XkdlAvOi9zIN88US=> M3r5W|czKGh? NYX4U5VS[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh MWCyN|g1PDJ{OB?=
HCC1569 Ml7zSpVv[3Srb36gRZN{[Xl? M2DxZVAvOi9zIN88US=> NHn4NHQ4OiCq M2H1dINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> MnTNNlM5PDR{Mki=
BT‑474 M1X2UWZ2dmO2aX;uJGF{e2G7 MnXwNE4zNzFizszN M1nmeVczKGh? MX3jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= MUWyN|g1PDJ{OB?=
AGS NFLyd|RCeG:ydH;zbZMhSXO|YYm= MmrTOU8yOC9{MD:1NEDPxE1? NYTUUJU4PDkEoHlCpC=> NW\zN|dVTE2VTx?= NWnQeIxkcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? NX;LTXhHOjN3OEK3PFQ>
A549 Mn61RZBweHSxc3nzJGF{e2G7 NIi4dVY2NzFyL{KwM|UxKM7:TR?= NFfPTXI1QMLiaNMg MnLZSG1UVw>? Mlq0bY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> NInMNoozOzV6Mke4OC=>
AGS  MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XRfFUwOTBxMkCvOVAh|ryP M1y0NFQ5yqCqwrC= NYewXox4TE2VTx?= NXvTW3N5cW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh NXLUSFdIOjN3OEK3PFQ>
Kasumi-1 M1nFSmFxd3C2b4Ppd{BCe3OjeR?= MkTwNE42KM7:TR?= NUe5NHpnPDkEoHlCpC=> M1jmV4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MViyN|Q6OzN2OB?=
OCI-AML3 MoG2RZBweHSxc3nzJGF{e2G7 NF64epgzNjVizszN MUS0POKhcMLi MlfV[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NELucWczOzR7M{O0PC=>
MV4-11 M2nuU2Fxd3C2b4Ppd{BCe3OjeR?= M13DS|IvPSEQvF2= NV;VUYNCPDkEoHlCpC=> M2S1VoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NImxWpgzOzR7M{O0PC=>
NK  NUjOZmVMS3m2b4TvfIl1gSCDc4PhfS=> NFiyPWQxNjB{LUKwJO69VQ>? Mkf6OUBl M{nXVIRm[3KnYYPld{B1cGViY4n0c4x6fGmlIHHjeIl3cXS7IH;mJG5MKGOnbHzzJIF1KGmwdHXycYVlcWG2ZTDjc45k\W62cnH0bY9veyC{ZYP1cJRqdmdiaX6gZUBWNXOqYYDl[EBld3On4pETdoV{eG:wc3WgZ5VzfmV? M4fIblI{OzJ6MEi4
NK  Ml;aRZBweHSxc3nzJGF{e2G7 NXTTUnp{OC5yMj2yNEDPxE1? MV[1JIQ> MmPJ[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl NFrFVIwzOzN{OEC4PC=>
NK  NWXsNY5OTnWwY4Tpc44hSXO|YYm= NYLse3psOC5yMT2yNEDPxE1? NXzvVIVxPSCm NVvYbGdb[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>? MXSyN|MzQDB6OB?=
MOLT4/DNR NWfXcXlqTnWwY4Tpc44hSXO|YYm= Mn[zOUDPxE1? NVvLOGREPCCm NV6ycmhKemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? MUGyN|A3ODV5MB?=
Jurkat/DOX NXTrV|Q1TnWwY4Tpc44hSXO|YYm= MVK1JO69VQ>? NEjrNIY1KGR? NFzFdXhz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? NYq5cZptOjNyNkC1O|A>
MOLT4/DNR NGLNSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHzOUDPxE1? M1\MOFQh\A>? NXznU2cxemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> NIG5SXczOzB4MEW3NC=>
Jurkat/DOX MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXy1JO69VQ>? NEXSXlg1KGR? MXjy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MomwNlMxPjB3N{C=
ccRCC  M1LHfGFxd3C2b4Ppd{BCe3OjeR?= NWPibHJZOC5yMT2xNO69VQ>? M4HXVlczKGh? MVXEUXNQ M{ewRohieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? M{fGSVIzQDJ4NE[3
TNBC  NGPxZXJCeG:ydH;zbZMhSXO|YYm= NVnk[3lWOC5yMT2xNO69VQ>? M13FclczKGh? NYn4c4dtTE2VTx?= MlrVbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? NXvROmxiOjJ6Mk[0Olc>
A498 MWrBdI9xfG:|aYOgRZN{[Xl? MlnBNE4xOS1zMN88US=> MWm3NkBp NHLW[5RFVVOR M{C5[Ylv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> M1X5XVIzQDJ4NE[3
KIJ265T MVXBdI9xfG:|aYOgRZN{[Xl? MW[wMlAyNTFyzszN MmHRO|IhcA>? NILUZ2NFVVOR MUHpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MmnSNlI5OjZ2Nke=
MDA-231 M{HzemFxd3C2b4Ppd{BCe3OjeR?= MWWwMlAyNTFyzszN MUC3NkBp NVe1dlVTTE2VTx?= Mlq2bY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M3vBb|IzQDJ4NE[3
BT-20 MWDBdI9xfG:|aYOgRZN{[Xl? NUjx[HZHOC5yMT2xNO69VQ>? MYi3NkBp M1f2fGROW09? NE\WUmhqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MWGyNlgzPjR4Nx?=
U937 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:xWIUxPS1{MDFOwG0> MVGyOE81QC95MjDo MXrpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MlfDNlI4PjdyMkG=
HL60 NFH3S2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnuU|c2NTJyIN88US=> NFfQ[3ozPC92OD:3NkBp M1LXb4lv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MUGyNlc3PzB{MR?=
U937 M3fJZ2Fxd3C2b4Ppd{BCe3OjeR?= M1XyU|E2KM7:TR?= MWiyOE81QC95MjDo M4DKWYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXKyNlc3PzB{MR?=
HL60 NHfqOmxCeG:ydH;zbZMhSXO|YYm= NVLJdINYOTVizszN Mn73NlQwPDhxN{KgbC=> NF\E[XRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MkiyNlI4PjdyMkG=
LS411N  M1jXVGFxd3C2b4Ppd{BCe3OjeR?= M4LEPVAvPSEQvF2= NH;wdGU4OiCq NYGzPVJpcW6lcnXhd4V{KE[jczDtVm5CKGyndnXs MY[yNlQ3OTZ7NR?=
MDA-MB-231 MWjBdI9xfG:|aYOgRZN{[Xl? MkTSNVAh|ryP MWm0PEBp Ml;NdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2K0U|IyQDh5Nkm3
MCF-7  MYfBdI9xfG:|aYOgRZN{[Xl? NILOT5EyOCEQvF2= MVO0PEBp MWfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXrwNo9pOjF6OEe2PVc>
A375 NHjOUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfWNFgxNjVizszN NFTIT2gyNzVxODDk NX23PGRJcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MmjYNlE4QTZ4MkK=
SKMEL1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSwMlUh|ryP NEjmVmEyNzVxODDk M4m0TYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NFf2dWUzOTd7Nk[yNi=>
SKMEL3 NUfFVWJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LlWlAvPSEQvF2= M4jCSlEwPS96IHS= NGnKVVBqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M2XjWFIyPzl4NkKy
SKMEL28 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT4S5YxNjVizszN MWixM|UwQCCm M{nTNolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NIPBb5kzOTd7Nk[yNi=>
MeWo NGfESpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKw[WIzOC53IN88US=> MXqxM|UwQCCm NY\ifYVrcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NVPkPYxHOjF5OU[2NlI>
B16 NIPRUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSwMlUh|ryP MkHkNU82NzhiZB?= NWfkOJFjcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NUPLZ2dROjF5OU[2NlI>
Ly 1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnizNlQhcA>? NYXvfWlMUUN3ME23MlMh|ryP NFP1eZUzOTd5MkC0PS=>
Ly 7 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYiyOEBp MlfJTWM2OD1zMD63JO69VQ>? M1ywVVIyPzd{MES5
Su-DHL6 MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7MN4JYOjRiaB?= MWXJR|Ux97zgMkCg{txO NWm5W5VGOjF5N{KwOFk>
Ly 10 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKyOEBp Mm\FTWM2OO,:nkKwJO69VQ>? NFXwbJUzOTd5MkC0PS=>
RIVA NEO1WXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13IfVI1KGh? M4HJO2lEPTExvK6yNEDPxE1? MYiyNVc4OjB2OR?=
Su-DHL2 M17Sb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr0NlQhcA>? M4nYU2lEPTExvK6yNEDPxE1? M{XPVFIyPzd{MES5
Ly 1 NUTkfmxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M162O|Q5KGh? NIDLeYdKSzVyPUCuN|Qh|ryP MVKyNVc4OjB2OR?=
Ly 7 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fLWlQ5KGh? M{f0b2lEPTB;MD6wNlUh|ryP MXuyNVc4OjB2OR?=
Su-DHL6 NXzEVlRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWradZlyPDhiaB?= NUP4S4E6UUN3MP-8olIxKM7:TR?= NIrRR3gzOTd5MkC0PS=>
Ly 10 NYDlWlhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L6cVQ5KGh? M1;ZbGlEPTB;MT64JO69VQ>? NUXWeWd{OjF5N{KwOFk>
RIVA NFzpTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfqd5o1QCCq NV[wPFl{UUN3MP-8olIxKM7:TR?= NELwS4czOTd5MkC0PS=>
Su-DHL2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;qOFghcA>? NE\jXJJKSzVyPUG3MlQh|ryP NGDLb3gzOTd5MkC0PS=>
Ly 1 NVzxfItGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWGxcJhIPzJiaB?= MmfjTWM2OD1yLkCxJO69VQ>? MlPvNlE4PzJyNEm=
Ly 7 M2X1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLnO|IhcA>? MUPJR|UxRTBwMEG4JO69VQ>? NVWxNlQ2OjF5N{KwOFk>
Su-DHL6 NFrGR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG5UpA4OiCq NFPkOWtKSzVyPUGuOkDPxE1? MViyNVc4OjB2OR?=
Ly 10 M1\2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH2eXpMPzJiaB?= MoDUTWM2OD1zLkKg{txO M1Tj[VIyPzd{MES5
RIVA NIDQNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTTeG8xPzJiaB?= NHzjXIJKSzVy78{eNlAh|ryP NYfjbYN1OjF5N{KwOFk>
Su-DHL2 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7wO|IhcA>? NYHidZgyUUN3ME2xNU4zKM7:TR?= MVuyNVc4OjB2OR?=

... Click to View More Cell Line Experimental Data
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing. 		10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4
CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03828084 Not yet recruiting Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03828084 Not yet recruiting Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03844815 Not yet recruiting Acute Myeloid Leukemia University of Chicago|AbbVie April 10 2019 Phase 1
NCT03844815 Not yet recruiting Acute Myeloid Leukemia University of Chicago|AbbVie April 10 2019 Phase 1
NCT03875287 Not yet recruiting Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals March 2019 Phase 1
NCT03875287 Not yet recruiting Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals March 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

selleck catalog

DNA Methyltransferase Signaling Pathway Map
Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID